PEPFAR’s Contribution to Laboratory Diagnostics in the context of 90-90-90 Joel Kuritsky, MD Dianna Edgil, PhD Jason Williams, MPH USAID Office of HIV/AIDS March 10-11, 2016
PEPFAR’s Contribution to Laboratory
Diagnostics in the context of 90-90-90
Joel Kuritsky, MD
Dianna Edgil, PhD
Jason Williams, MPH
USAID Office of HIV/AIDS
March 10-11, 2016
2 Total lab spend $854,441,687
SCMS Non-Pharma Spend 2008-2015
3
SCMS Non-Pharma Spend 2008-2015
4
PEPFAR HIV POC Rapid Tests: Countries Served 2014-2015 (count of individual tests)
SCMS HIV RTKs Delivered
SCMS HIV RTKs Delivery, 2014-2015
GHSC-RTK HIV POC Rapid Test Pipeline (individual tests)
8
CD4 Instrument Totals
Molecular Instrument Totals
10
SCMS Total CD4 Spend (Oct 2015)
11
Total Molecular Spend—VL/EID (inclusive of instruments) (Oct 2015)
Molecular Instrument Totals
Coordination and Site Visits
• Coordinated procurement/forecasting
• Bundling of service maintenance/training with procurement
• With other TWGs—site visits December 2015—March 2016
• 1) Malawi—80k tests/11 platforms (sample rejection,
demand)
• 2) Uganda—200k tests/8 platforms (HR)
• 3) Swaziland—36k tests/2 platforms(HR, backlog, transport)
• 4) Kenya—750k/32 platforms (backlog)
• 5) Mozambique (pending)
• 6) Tanzania (pending) —14k tests/8 platforms
Achievements to Date in VL Scale up
Key Issues for COP16 Planning
VL scale up issues
1)Increasing instrument use/catch-up with backlog/switch from
CD4
2)Increasing responsibility of the manufacturers in
service/maintenance
3)HR/training/transport lanes
Quality assurance issues:
1)Collaboration with WHO PQ
2)Agreement with GDWG
PEPFAR’s Contribution to Laboratory
Diagnostics in the context of 90-90-90
Joel Kuritsky, MD
Dianna Edgil, PhD
Jason Williams, MPH
USAID Office of HIV/AIDS
March 10-11, 2016